Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Circulationarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Circulation
Article
Data sources: UnpayWall
Circulation
Article . 2015 . Peer-reviewed
Data sources: Crossref
Circulation
Article . 2016
versions View all 2 versions
addClaim

This Research product is the result of merged Research products in OpenAIRE.

You have already added 0 works in your ORCID record related to the merged Research product.

Drug Therapy for Heart Valve Diseases

Authors: Jeffrey S, Borer; Abhishek, Sharma;

Drug Therapy for Heart Valve Diseases

Abstract

Valvular heart diseases (VHDs) are among the most predictable causes of heart failure and sudden cardiac death.1 Observational studies suggest that a relatively high proportion of asymptomatic subjects manifest hemodynamically apparent VHDs varying from mild to severe.1 VHDs comprise 2 overarching groups: primary, involving intrinsic abnormalities of valve structures, and secondary, or “functional,” featuring myocardial dysfunction or vascular deformation that secondarily affects valve performance. Clinically, VHDs generally are progressive. When hemodynamically severe but not caused by acute comorbidities (eg, infection, myocardial infarction) they feature long asymptomatic phases while hemodynamic severity may progress, followed by symptoms or objective descriptors that predict morbidity and mortality and are considered to mandate surgery. Treatment depends on VHD type and severity but, when severe and symptomatic, usually involves mechanical intervention. Asymptomatic patients who lack objective descriptors suggesting high morbid or lethal risk are closely observed clinically (and associated cardiovascular risk factors are optimized) until surgical indications develop. Although often prescribed based on theory, no rigorous evidence supports pharmacological therapy in most chronic situations, although drugs may be useful in acute valvular diseases, or as a bridge to surgery in severely decompensated patients. This review examines evidence supporting the use of drugs for chronic VHDs. We will focus only on drugs believed to prevent clinical, cardiac functional, or valve abnormalities or to delay surgery and will avoid discussion of anticoagulants and specific antiarrhythmics that might be appropriate in certain settings. Finally, given the volume of available clinical data and the paucity of drugs developed solely for VHD, we will present animal or experimental data only when they importantly supplement clinical information (Table). View this table: Table. Effects of Drugs on Functional Measures, Progression, and Clinical Outcomes of VHD Aortic stenosis (AS) is the most common VHD in adults, increasing in prevalence with age.2 AS presents a …

Related Organizations
Keywords

Diphosphonates, Vasodilator Agents, Adrenergic beta-Antagonists, Heart Valve Diseases, Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Antagonists, Disease Models, Animal, Drug Therapy, Animals, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    42
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    Top 10%
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    Top 10%
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    Top 10%
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
42
Top 10%
Top 10%
Top 10%
bronze